Sage Therapeutics (NASDAQ:SAGE) Posts Earnings Results, Misses Expectations By $0.17 EPS

Sage Therapeutics (NASDAQ:SAGE) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($1.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.63) by ($0.17), Briefing.com reports. Sage Therapeutics had a negative return on equity of 54.41% and a negative net margin of 626.32%. The firm had revenue of $7.90 million for the quarter, compared to analysts’ expectations of $5.26 million. During the same period in the previous year, the business posted ($2.46) EPS. The business’s revenue for the quarter was up 139.4% compared to the same quarter last year.

Sage Therapeutics Stock Up 0.8 %

NASDAQ SAGE traded up $0.11 on Friday, reaching $13.69. The company had a trading volume of 1,493,679 shares, compared to its average volume of 1,034,531. Sage Therapeutics has a 52 week low of $10.92 and a 52 week high of $59.99. The stock has a market cap of $822.91 million, a price-to-earnings ratio of -1.53 and a beta of 0.86. The stock’s 50 day moving average is $18.75 and its 200-day moving average is $20.68.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on SAGE shares. Scotiabank dropped their target price on shares of Sage Therapeutics from $34.00 to $19.00 and set a “sector outperform” rating for the company in a research note on Thursday, April 18th. Canaccord Genuity Group lowered their price target on Sage Therapeutics from $21.00 to $17.00 and set a “hold” rating on the stock in a report on Friday. Bank of America lowered Sage Therapeutics from a “neutral” rating to an “underperform” rating and dropped their target price for the stock from $24.00 to $14.00 in a report on Wednesday, April 17th. StockNews.com downgraded Sage Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, April 19th. Finally, Wedbush restated a “neutral” rating and issued a $24.00 target price on shares of Sage Therapeutics in a research note on Wednesday, April 17th. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and three have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $37.72.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.